Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Provides Business Update

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
February 25, 2025 08:05 ET | Source: Organovo, Inc.

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
November 13, 2024 08:06 ET | Source: Organovo, Inc.

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
January 25, 2024 08:05 ET | Source: Organovo, Inc.

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
November 08, 2023 08:05 ET | Source: Organovo, Inc.

Organovo Highlights FXR314 Combination Therapy Potential and Plan

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
February 23, 2022 08:05 ET | Source: Organovo, Inc.

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to...
July 08, 2019 08:05 ET | Source: Organovo, Inc.

Organovo Presents Data on Creating Stem Cell-Based Bioprinted Kidney Organoids at the International Society for Stem Cell Research (ISSCR) 2019 Annual Meeting

SAN DIEGO, July 08, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range...
May 18, 2017 08:05 ET | Source: Organovo, Inc.

Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress

SAN DIEGO, May 18, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs...
May 01, 2017 08:05 ET | Source: Organovo, Inc.

Organovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric Muscle Loss Injury

SAN DIEGO, May 01, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs...
October 11, 2016 08:05 ET | Source: Organovo, Inc.

Organovo Announces Select Preliminary Second-Quarter 2017 Results; Company Updates Full-Year Fiscal 2017 Outlook

SAN DIEGO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs...

Next Page keyboard_arrow_right